NO20091197L - Azabenzofuranylforbindelser og anvendelser derav - Google Patents
Azabenzofuranylforbindelser og anvendelser deravInfo
- Publication number
- NO20091197L NO20091197L NO20091197A NO20091197A NO20091197L NO 20091197 L NO20091197 L NO 20091197L NO 20091197 A NO20091197 A NO 20091197A NO 20091197 A NO20091197 A NO 20091197A NO 20091197 L NO20091197 L NO 20091197L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- treat
- methods
- relates
- azabenzofuranyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 abstract 1
- 108060006687 MAP kinase kinase kinase Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83916106P | 2006-08-21 | 2006-08-21 | |
| US87159106P | 2006-12-22 | 2006-12-22 | |
| US91762307P | 2007-05-11 | 2007-05-11 | |
| US94474107P | 2007-06-18 | 2007-06-18 | |
| PCT/US2007/076344 WO2008024725A1 (en) | 2006-08-21 | 2007-08-20 | Aza-benzofuranyl compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20091197L true NO20091197L (no) | 2009-05-20 |
Family
ID=38925647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20091197A NO20091197L (no) | 2006-08-21 | 2009-03-20 | Azabenzofuranylforbindelser og anvendelser derav |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20080085886A1 (es) |
| EP (1) | EP2069354B1 (es) |
| JP (1) | JP5448818B2 (es) |
| KR (1) | KR101428116B1 (es) |
| AR (1) | AR062468A1 (es) |
| AT (1) | ATE531720T1 (es) |
| AU (1) | AU2007286808B2 (es) |
| BR (1) | BRPI0714635A2 (es) |
| CA (1) | CA2660546A1 (es) |
| ES (1) | ES2376771T3 (es) |
| IL (1) | IL196956A (es) |
| MX (1) | MX2009001878A (es) |
| NO (1) | NO20091197L (es) |
| PE (1) | PE20080611A1 (es) |
| TW (1) | TWI411614B (es) |
| WO (1) | WO2008024725A1 (es) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2660963A1 (en) * | 2006-08-21 | 2008-02-28 | Genentech, Inc. | Aza-benzothiophenyl compounds and methods of use |
| WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
| EP2085390A1 (en) * | 2008-01-31 | 2009-08-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Labelled analogues of halobenzamides as multimodal radiopharmaceuticals and their precursors |
| JP5651125B2 (ja) | 2008-12-10 | 2015-01-07 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異 |
| BRPI1015525A2 (pt) | 2009-04-14 | 2015-09-01 | Nissan Chemical Ind Ltd | Derivados de haloalquilsulfonanilida, seus usos, seus intermediários e seu método de uso, bem como agroquímico e herbicida |
| CN102134218A (zh) * | 2009-06-15 | 2011-07-27 | 凯美隆(北京)药业技术有限公司 | 6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂 |
| MX360932B (es) | 2010-02-25 | 2018-11-21 | Dana Farber Cancer Inst Inc | Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf. |
| MX343368B (es) | 2010-03-09 | 2016-11-01 | The Broad Inst Inc * | Metodo de diagnostico y tratamiento de cancer en pacientes que tienen o desarrollan resistencia a una primera terapia de cancer. |
| WO2012071458A1 (en) | 2010-11-22 | 2012-05-31 | Array Biopharma Inc. | Heterocyclic inhibitors of beta - secretase for the treatment of neurodegenerative diseases |
| US9328066B2 (en) | 2011-05-27 | 2016-05-03 | Bayer Intellectual Property Gmbh | Chiral synthesis of N-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfonamides |
| BR112014002353B1 (pt) * | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| AU2013337702A1 (en) | 2012-11-02 | 2015-05-21 | Merck Patent Gmbh | Method of reducing adverse effects in a cancer patient undergoing treatment with a MEK inhibitor |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| WO2015138920A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| US20170114323A1 (en) | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| CN116617401A (zh) | 2014-07-15 | 2023-08-22 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和mek抑制剂治疗癌症的组合物 |
| EP3191127A1 (en) | 2014-09-13 | 2017-07-19 | Novartis AG | Combination therapies of egfr inhibitors |
| EP3200775B1 (en) | 2014-10-03 | 2019-11-20 | Novartis AG | Combination therapies |
| PE20171067A1 (es) | 2014-10-14 | 2017-07-24 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
| CN114272371A (zh) | 2015-07-29 | 2022-04-05 | 诺华股份有限公司 | 包含抗pd-1抗体分子的联合疗法 |
| EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| WO2017019894A1 (en) | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
| CN108697791B (zh) | 2015-11-03 | 2022-08-23 | 詹森生物科技公司 | 特异性结合pd-1的抗体及其用途 |
| CN106883270B (zh) | 2015-11-26 | 2019-03-26 | 财团法人工业技术研究院 | 有机金属化合物、包含其的有机发光装置 |
| MX2018007423A (es) | 2015-12-17 | 2018-11-09 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas. |
| KR20180134347A (ko) | 2016-04-15 | 2018-12-18 | 제넨테크, 인크. | 암의 진단 및 치료 방법 |
| CA3063535A1 (en) * | 2017-05-19 | 2018-11-22 | Nflection Therapeutics, Inc. | Fused heteroaromatic-aniline compounds for treatment of dermal disorders |
| CN111065393B (zh) | 2017-05-19 | 2023-08-18 | 恩福莱克逊治疗有限公司 | 用于治疗皮肤疾病的吡咯并吡啶-苯胺类化合物 |
| JP7530829B2 (ja) | 2017-09-08 | 2024-08-08 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | がんの診断及び治療方法 |
| KR20200089286A (ko) | 2017-11-16 | 2020-07-24 | 노파르티스 아게 | 조합 요법 |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| US20210008047A1 (en) | 2018-02-13 | 2021-01-14 | Vib Vzw | Targeting minimal residual disease in cancer with rxr antagonists |
| PE20211916A1 (es) | 2018-05-24 | 2021-09-28 | Janssen Biotech Inc | Agentes aglutinantes del psma y usos de estos |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CN113473978B (zh) | 2018-11-20 | 2025-03-28 | 恩福莱克逊治疗有限公司 | 用于治疗皮肤疾病氰基芳烃-苯胺化合物 |
| JP7393808B2 (ja) | 2018-11-20 | 2023-12-07 | エヌフレクション セラピューティクス インコーポレイテッド | 皮膚障害の処置のためのナフチリジノン－アニリン化合物 |
| CA3120352A1 (en) | 2018-11-20 | 2020-05-28 | Nflection Therapeutics, Inc. | Thienyl-aniline compounds for treatment of dermal disorders |
| CA3123511A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| MX2021009764A (es) | 2019-02-15 | 2021-09-08 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos. |
| ES3032659T3 (en) | 2019-02-15 | 2025-07-23 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| AR118720A1 (es) | 2019-04-19 | 2021-10-27 | Janssen Biotech Inc | Métodos para tratar el cáncer de próstata con un anticuerpo anti-psma / cd3 |
| CN115175937A (zh) | 2019-12-20 | 2022-10-11 | 诺华股份有限公司 | 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合 |
| WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| EP4284838A2 (en) | 2021-01-28 | 2023-12-06 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
| CA3206906A1 (en) | 2021-02-02 | 2022-08-11 | Andras Herner | Selective bcl-xl protac compounds and methods of use |
| CN117321418A (zh) | 2021-03-18 | 2023-12-29 | 诺华股份有限公司 | 癌症生物标志物及其使用方法 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| US12371667B2 (en) | 2021-05-13 | 2025-07-29 | Washington University | Enhanced methods for inducing and maintaining naive human pluripotent stem cells |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| KR20250027281A (ko) | 2022-05-20 | 2025-02-25 | 노파르티스 아게 | Epha2 bcl-xl 억제제 항체-약물 접합체 및 그의 사용 방법 |
| AU2023273734A1 (en) | 2022-05-20 | 2024-12-12 | Les Laboratoires Servier | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| WO2024033381A1 (en) | 2022-08-10 | 2024-02-15 | Vib Vzw | Inhibition of tcf4/itf2 in the treatment of cancer |
| CN120752058A (zh) | 2023-03-10 | 2025-10-03 | 诺华股份有限公司 | panRAS抑制剂抗体-药物缀合物及其使用方法 |
| WO2025111450A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd74 antibody-drug conjugates and methods of use thereof |
| WO2025215536A1 (en) | 2024-04-10 | 2025-10-16 | Novartis Ag | Macrocyclic panras inhibitors for the treatment of cancer |
| CN119285968B (zh) * | 2024-09-19 | 2025-06-20 | 黑龙江大学 | 一种光致变色稀土聚合物及其制备方法和应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5328920A (en) * | 1991-04-17 | 1994-07-12 | Hoechst-Roussel Pharmaceuticals Incorporated | Substituted (pyridinylamino)-indoles |
| US5214204A (en) * | 1991-07-19 | 1993-05-25 | Abbott Laboratories | Arylamidoalkyl-n-hydroxyurea compounds having lipoxygenase inhibitory activity |
| EP0530537B1 (en) * | 1991-08-12 | 1997-01-08 | Takeda Chemical Industries, Ltd. | Condensed pyrimidine derivatives, their production and use as antitumor agents |
| CA2083891A1 (en) * | 1991-12-03 | 1993-06-04 | Angus Murray Macleod | Heterocyclic compounds, compositions containing them and their use in therapy |
| JPH05345780A (ja) * | 1991-12-24 | 1993-12-27 | Kumiai Chem Ind Co Ltd | ピリミジンまたはトリアジン誘導体及び除草剤 |
| US5852046A (en) * | 1993-08-03 | 1998-12-22 | Hoechst Aktiengesellschaft | Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them |
| US5350748A (en) * | 1993-08-18 | 1994-09-27 | Warner-Lambert Company | 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion |
| DE4425609A1 (de) * | 1994-07-20 | 1996-01-25 | Bayer Ag | Benzofuranyl- und Benzothienyloxazolidinone |
| FR2777886B1 (fr) * | 1998-04-27 | 2002-05-31 | Adir | Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6410562B1 (en) * | 1998-12-18 | 2002-06-25 | Eli Lilly And Company | Hypoglycemic imidazoline compounds |
| DE69926800T2 (de) * | 1999-01-13 | 2006-05-18 | Warner-Lambert Company Llc | Benzoheterozyklen und ihre verwendung als mek inhibitoren |
| JP2000204079A (ja) * | 1999-01-13 | 2000-07-25 | Warner Lambert Co | ジアリ―ルアミン |
| FR2799756B1 (fr) * | 1999-10-15 | 2001-12-14 | Adir | Nouveaux derives benzothiopheniques, benzofuraniques et indoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| DZ3401A1 (fr) * | 2000-07-19 | 2002-01-24 | Warner Lambert Co | Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques |
| DE10110750A1 (de) * | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| US6653346B1 (en) * | 2002-02-07 | 2003-11-25 | Galileo Pharmaceuticals, Inc. | Cytoprotective benzofuran derivatives |
| PA8569301A1 (es) * | 2002-03-13 | 2004-10-08 | Array Biopharma Inc | "derivados de bencimidazol n3 alquilado como inhibidores de mek" "n3 alkylated benzimidazole derivatives as mek inhibitors" |
| KR20040098013A (ko) * | 2002-03-13 | 2004-11-18 | 어레이 바이오파마 인크. | Ｍｅｋ 억제제로서의 ｎ3 알킬화된 벤즈이미다졸 유도체 |
| US20040009976A1 (en) * | 2002-04-30 | 2004-01-15 | Kumiko Takeuchi | Hypoglycemic imidazoline compounds |
| CL2003002287A1 (es) * | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPUESTOS DERIVADOS DE TIENO[3,2-b]-PIRIDINA-6-CARBONITRILOS Y TIENEO[2,3-b]-PIRIDINA-5-CARBONITRILOS, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION Y COMPUESTOS INTERMEDIARIOS, Y SU USO EN EL TRATAMIENTO DEL CANCER, APOPLEJIA, OSTEOPOROSIS |
| JP2005104838A (ja) * | 2003-01-09 | 2005-04-21 | Tanabe Seiyaku Co Ltd | 縮合フラン化合物 |
| US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| DE10351436A1 (de) * | 2003-11-04 | 2005-06-09 | Merck Patent Gmbh | Verwendung von Thienopyrimidinen |
| ES2338060T3 (es) * | 2003-12-22 | 2010-05-03 | Basilea Pharmaceutica Ag | Componentes de tipo ariloxi y ariltoxia-cetofenona para el tratamiento del cancer. |
| US20090275570A1 (en) * | 2005-04-06 | 2009-11-05 | Astrazeneca Ab | Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors |
| CA2620864A1 (en) * | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
| TWI389895B (zh) * | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法 |
| CA2660963A1 (en) * | 2006-08-21 | 2008-02-28 | Genentech, Inc. | Aza-benzothiophenyl compounds and methods of use |
| MX2009003102A (es) * | 2006-09-21 | 2009-04-01 | Wyeth Corp | INDOLILALQUILPIRIDIN-2-AMINAS PARA LA INHIBICION DE ß-SECRETASA. |
-
2007
- 2007-08-20 CA CA002660546A patent/CA2660546A1/en not_active Abandoned
- 2007-08-20 AT AT07814272T patent/ATE531720T1/de active
- 2007-08-20 ES ES07814272T patent/ES2376771T3/es active Active
- 2007-08-20 MX MX2009001878A patent/MX2009001878A/es active IP Right Grant
- 2007-08-20 AU AU2007286808A patent/AU2007286808B2/en not_active Ceased
- 2007-08-20 KR KR1020097005786A patent/KR101428116B1/ko not_active Expired - Fee Related
- 2007-08-20 WO PCT/US2007/076344 patent/WO2008024725A1/en not_active Ceased
- 2007-08-20 BR BRPI0714635-3A patent/BRPI0714635A2/pt not_active IP Right Cessation
- 2007-08-20 JP JP2009525720A patent/JP5448818B2/ja not_active Expired - Fee Related
- 2007-08-20 US US11/894,506 patent/US20080085886A1/en not_active Abandoned
- 2007-08-20 EP EP07814272A patent/EP2069354B1/en active Active
- 2007-08-21 TW TW096130982A patent/TWI411614B/zh not_active IP Right Cessation
- 2007-08-21 AR ARP070103712A patent/AR062468A1/es unknown
- 2007-08-21 PE PE2007001135A patent/PE20080611A1/es not_active Application Discontinuation
-
2009
- 2009-02-09 IL IL196956A patent/IL196956A/en not_active IP Right Cessation
- 2009-03-20 NO NO20091197A patent/NO20091197L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2376771T3 (es) | 2012-03-16 |
| KR20090042332A (ko) | 2009-04-29 |
| IL196956A (en) | 2014-04-30 |
| TWI411614B (zh) | 2013-10-11 |
| JP5448818B2 (ja) | 2014-03-19 |
| BRPI0714635A2 (pt) | 2013-06-18 |
| US20080085886A1 (en) | 2008-04-10 |
| AU2007286808B2 (en) | 2012-12-06 |
| MX2009001878A (es) | 2009-03-03 |
| ATE531720T1 (de) | 2011-11-15 |
| CA2660546A1 (en) | 2008-02-28 |
| AU2007286808A1 (en) | 2008-02-28 |
| EP2069354A1 (en) | 2009-06-17 |
| WO2008024725A1 (en) | 2008-02-28 |
| JP2010501585A (ja) | 2010-01-21 |
| KR101428116B1 (ko) | 2014-08-07 |
| AR062468A1 (es) | 2008-11-12 |
| EP2069354B1 (en) | 2011-11-02 |
| PE20080611A1 (es) | 2008-07-21 |
| IL196956A0 (en) | 2009-11-18 |
| TW200817415A (en) | 2008-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20091197L (no) | Azabenzofuranylforbindelser og anvendelser derav | |
| NO20091198L (no) | Azabenzotiofenylforbindelser og anvendelser derav | |
| DK2231662T3 (da) | 8-Anilinoimidazopyridiner og deres anvendelse som anticancer- og/eller antiinflammatoriske midler | |
| WO2010003022A8 (en) | Isoindolone derivatives as mek kinase inhibitors and methods of use | |
| MY158829A (en) | 5-anilinoimidazopyridines and methods of use | |
| WO2008157179A3 (en) | N-substituted azaindoles and methods of use | |
| NO20074473L (no) | RAF-inhibitorforbindelser og -fremgangsmater | |
| TR201909849T4 (tr) | Btk etkinliği inhibitörleri olarak heteroaril piridon ve aza-piridon bileşikleri. | |
| WO2009111278A3 (en) | Raf inhibitor compounds and methods of use thereof | |
| UA111933C2 (uk) | Піролопіридини як інгібітори кінази | |
| WO2011025938A3 (en) | Raf inhibitor compounds and methods of use thereof | |
| SG178986A1 (en) | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use | |
| EA200801716A1 (ru) | Тиазольные соединения и их применение | |
| WO2009151598A8 (en) | Diazacarbazoles and methods of use | |
| BR112014021634A8 (pt) | inibidores de serina/treonina quinase,composições que os compreendem, seus usos e seus processos de preparação, e método de inibir a atividade da proteína quinase erk em uma célula | |
| NO20081595L (no) | Raf-inhibitorforbindelser og fremgangsmater for anvendelse derav | |
| MX2014005282A (es) | Compuestos de 8-fluoroftalazin-1 (2h) -ona. | |
| NO20084927L (no) | Fosfoinositid-3-kinaseinhibitorforbindelser og farmasoytiske sammensetninger inneholdende dem | |
| WO2009012109A3 (en) | Cyanine-containing compounds for cancer imaging and treatment | |
| CR11690A (es) | Pirazolo (3,4-b) piridinas como inhibidores de raf | |
| EA201490859A1 (ru) | Алкилированные соединения пиперазина в качестве ингибиторов тирозинкиназы брутона | |
| SG178900A1 (en) | Raf inhibitor compounds and methods of use thereof | |
| MX2010001993A (es) | Metodos y composiciones para diagnosticar una enfermedad. | |
| MX2012006822A (es) | 1,7-diazacarbazoles y metodos de uso. | |
| WO2007015175A3 (en) | Use of pp-1 inhibitors to prevent missplicing events |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |